ENTOD Pharma unveils state-of-the-art R&D facility in Navi Mumbai

The brand new additional R&D facility in Navi Mumbai has been designed with state-of-the-art equipment and the latest analytical & formulation research tools

ENTOD Pharmaceuticals recently inaugurated its new state-of-the-art R&D facility in Navi Mumbai to further enhance its innovation capability, a company statement notified.

The R&D centre was inaugurated recently by its group chairman Kishore Masurkar. “We dedicate this research facility to our founder, the late Mr GV Masurkar on the occasion of his 100th birth anniversary year, whose passion for pharmaceutical research, therapeutic innovation and entrepreneurship made him into a pharmaceutical visionary & pioneer of his times,” Kishore Masurkar said.

The brand new additional R&D facility in Navi Mumbai has been designed with state-of-the-art equipment and the latest analytical and formulation research tools.

The advanced research facility is approved by the Department of Scientific & Industrial Research (DSIR) and will focus on ophthalmic, ENT and dermatology formulation development. It will allow the corporation to further engage in new product development, formulation and molecular research.

“Our new R&D facility in Navi Mumbai raises the bar for sustainable R&D and global collaboration across the industry. It will allow us to break new boundaries in bringing life-changing medicines to patients and power the next stage of our company’s growth. The R&D expansion broadens our presence in the country while also acknowledging the country’s specialised capabilities and potential. India has a very mature pharmaceutical market. If Indian pharmaceutical businesses wish to advance in terms of value, they should concentrate on how to deepen their R&D and inventions. With the G20 presidency, India has an opportunity to set the global agenda and promote inclusive and sustainable industrialisation and foster innovation. In particular, we feel that India’s G20 Presidency will encourage innovation and substantially increase the numbers of researchers as well as public and private spending on R&D. Given India’s G20 Presidency, we believe that digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023,” said its CEO Nikkhil K Masurkar who also attended the inauguration event.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button